Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Amortization of Deferred Charges (2022 - 2025)

Immucell (ICCC) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $29579.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Amortization of Deferred Charges rose 173.75% year-over-year to $29579.0, compared with a TTM value of $61998.0 through Sep 2025, up 47.78%, and an annual FY2024 reading of $42666.0, up 88.63% over the prior year.
  • Amortization of Deferred Charges was $29579.0 for Q3 2025 at Immucell, up from $10806.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $29579.0 in Q3 2025 and bottomed at $1915.0 in Q2 2022.
  • Average Amortization of Deferred Charges over 4 years is $9254.6, with a median of $10247.0 recorded in 2024.
  • The sharpest move saw Amortization of Deferred Charges skyrocketed 463.16% in 2024, then decreased 0.01% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $1919.0 in 2022, then surged by 426.0% to $10094.0 in 2023, then increased by 7.06% to $10807.0 in 2024, then surged by 173.7% to $29579.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for ICCC at $29579.0 in Q3 2025, $10806.0 in Q2 2025, and $10806.0 in Q1 2025.